FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment - Eli Lilly (NYSE:LLY)

FDA clears new, safer regimen for Lilly's Alzheimer's drug

Eli Lilly has won FDA approval for a new regimen for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of side effects

FDA Approves Updated Label With New Dosing For Lilly's Alzheimer's Drug ...

Lilly gets FDA OK of modified dosing for Alzheimer’s drug

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to prescribe Lilly’s amyloid-busting drug.

FDA approves new dosing schedule for Lilly’s Alzheimer’s drug Kisunla

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new...

FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment - Eli Lilly (NYSE:LLY)

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid plaque reduction.